Table 1.
Baseline characteristics
| Overall n = 96 |
PRU < 208 n = 73 |
PRU ≥ 208 n = 23 |
p value | |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Male | 75 (78.1) | 62 (84.9) | 13 (56.5) | 0.008 |
| Female | 21 (21.9) | 11 (15.1) | 10 (43.5) | |
| Age, years | ||||
| Mean ± SD | 69.9 ± 9.6 | 68.6 ± 9.9 | 74.0 ± 7.3 | 0.020 |
| Median [range] | 71.0 [42–89] | 69.0 [42–89] | 74.0 [60–89] | |
| Height, cm | ||||
| Mean ± SD | 161.73 ± 7.22 | 162.58 ± 7.17 | 159.00 ± 6.84 | 0.038 |
| Median [range] | 162.95 [144.6–173.0] | 164.50 [144.6–173.0] | 158.50 [147.8–172.5] | |
| BMI, kg/m2 | ||||
| Mean ± SD | 25.06 ± 3.27 | 25.40 ± 3.49 | 23.96 ± 2.16 | 0.064 |
| Median [range] | 24.90 [15.1–36.4] | 25.42 [15.1–36.4] | 24.06 [20.3–27.5] | |
| Weight, kg | ||||
| Mean ± SD | 65.76 ± 10.74 | 67.36 ± 11.11 | 60.70 ± 7.69 | 0.009 |
| Median [range] | 65.10 [33.5–91.0] | 68.70 [33.5–91.0] | 61.60 [44.7–77.2] | |
| Smoking history, n (%) | ||||
| Never | 47 (49.0) | 32 (43.8) | 15 (65.2) | 0.095 |
| Yes | 49 (51.0) | 41 (56.2) | 8 (34.8) | |
| Medical history, n (%) | ||||
| Myocardial infarction | 54 (56.3) | 42 (57.5) | 12 (52.2) | 0.810 |
| Unstable angina | 25 (26.0) | 23(31.5) | 2 (8.7) | 0.032 |
| Ischemic stroke | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Hemorrhage intracranial | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Arteriosclerosis | 23 (24.0) | 17 (23.3) | 6 (26.1) | 0.784 |
| Stable angina pectoris | 30 (31.3) | 20 (27.4) | 10 (43.5) | 0.197 |
| Complication, n (%) | ||||
| Hypertension | 91 (94.8) | 69 (94.5) | 22 (95.7) | 1.000 |
| Dyslipidemia | 90 (93.8) | 67 (91.8) | 23 (100.0) | 0.330 |
| Diabetes mellitus | 58 (60.4) | 44 (60.3) | 14 (60.9) | 1.000 |
| Hepatic function disorder | 3 (3.1) | 2 (2.7) | 1(4.3) | 0.565 |
| Renal function disorder | 11 (11.5) | 6 (8.2) | 5 (21.7) | 0.126 |
| Atrial fibrillation | 1 (1.0) | 0 (0.0) | 1 (4.3) | 0.240 |
| Clopidogrel dose, mg | ||||
| Mean ± SD | 74.7 ± 2.6 | 74.7 ± 2.9 | 75.0 ± 0.0 | 0.577 |
| Median [range] | 75.0 [50–75] | 75.0 [50–75] | 75.0 [75–75] | |
| Duration of DAPT, days | ||||
| Mean ± SD | 1784.7 ± 834.0 | 1793.9 ± 847.3 | 1757.6 ± 811.3 | 0.858 |
| Median [range] | 1824.0 [375–3603] | 1696.0 [375–3603] | 1866.0 [404–3473] | |
| Duration of Clopidogrel administration, days | ||||
| Mean ± SD | 1785.4 ± 838.8 | 1797.0 ± 846.6 | 1751.2 ± 833.2 | 0.823 |
| Median [range] | 1866.0 [161–3473] | 1866.0 [346–3436] | 1866.0 [161–3473] | |
| PRU at baseline | ||||
| Mean ± SD | 166.9 ± 59.8 | 144.1 ± 47.0 | 239.3 ± 31.7 | < 0.001 |
| Median [range] | 165.0 [5–341] | 155.0 [5–207] | 228.0 [208–341] | |
| CYP2C19 polymorphism, n (%) | ||||
| EM | 34 (35.4) | 29 (39.7) | 5 (21.7) | 0.228 |
| IM | 50 (52.1) | 36 (49.3) | 14 (60.9) | |
| PM | 12 (12.5) | 8 (11.0) | 4 (17.4) | |
| IM + PM | 62 (64.6) | 44 (60.3) | 18 (78.3) | 0.139a |
| DAPT score, n (%) | ||||
| < 2 | 32 (33.3) | 22 (30.1) | 10 (43.5) | 0.301 |
| ≥ 2 | 55 (57.3) | 44 (60.3) | 11 (47.8) | |
An independent t test was used for measurement data, and a Fisher’s exact test was performed for count data
EM extensive metabolizer, IM intermediate metabolizer, PM poor metabolizer
aCompared with EM